Form 4: RA Capital Affiliated Director Granted Stock Options in Cidara Therapeutics

A Form 4 filing reveals that Joshua Resnick, a director of Cidara Therapeutics affiliated with RA Capital Management, L.P., was granted 5,079 stock options with an exercise price of $21.31, vesting by June 2026.

Summary

• RA Capital Management, L.P., RA Capital Healthcare Fund LP, Peter Kolchinsky, and Rajeev Shah filed a Form 4 regarding transactions in Cidara Therapeutics, Inc. (CDTX).
• The filing reports the grant of an annual director stock option to Joshua Resnick, a Partner of RA Capital Management, L.P. and a director of Cidara Therapeutics.
• The option is for 5,079 shares of common stock, pro-rated from a full annual grant of 11,100 shares based on Dr. Resnick's service period.
• The exercise price for these options is $21.31 per share.
• The options were granted on June 18, 2025, and expire on June 17, 2035.
• The shares subject to the option will vest on the earlier of June 18, 2026, or the day prior to Cidara's 2026 annual meeting of stockholders.
• The economic benefit of the option flows to RA Capital Healthcare Fund, L.P., as Dr. Resnick holds the option for the benefit of the Fund and is obligated to turn over any net proceeds to the Adviser, offsetting advisory fees.

Sentiment

Score: 6

Explanation: The document reports a routine director stock option grant, which is a neutral event. The alignment of interests is positive, but potential dilution is a minor negative. Overall, it's an expected and standard corporate action.

Positives

• The granting of stock options to a director aligns the director's interests with those of the shareholders, promoting long-term value creation.
• The option grant is part of a standard non-employee director compensation policy, indicating routine and structured corporate governance practices.

Negatives

• The issuance of new stock options can lead to potential future dilution for existing shareholders if and when the options are exercised.

Risks

• Potential future dilution of existing shareholder equity upon the exercise of the granted stock options.

Future Outlook

The document indicates future vesting of the granted stock options by June 18, 2026, or prior to the 2026 annual meeting of stockholders, and an expiration date of June 17, 2035, for the options.

Industry Context

This filing is a routine disclosure of director compensation in the biotechnology/pharmaceutical industry. Stock option grants are a common method to incentivize and align the interests of non-employee directors with shareholders, particularly in growth-oriented sectors like biotech where long-term value creation is key.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation practice across publicly traded companies, including those in the biotechnology sector.
• The pro-rated nature of the grant based on service is also a common adjustment for directors joining mid-cycle or for specific service periods.
• While specific comparable companies or projects are not mentioned, the structure of this compensation aligns with typical governance practices for director equity awards in the industry.

Corporate Governance

Related Party Transactions

• The stock option grant to Joshua Resnick, a Partner of RA Capital Management, L.P., which is a 10% owner and has other affiliated individuals serving as directors, constitutes a related party transaction.
• Dr. Resnick holds the option for the benefit of RA Capital Healthcare Fund, L.P., and is obligated to turn over net proceeds to RA Capital Management, L.P., which offsets advisory fees owed by the Fund. This arrangement further highlights the related party nature of the transaction and the flow of economic benefit to the investment firm.

Stakeholder Impact

• Shareholders: Potential minor dilution from future exercise of options; improved alignment of director interests with shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of the granted stock options on or before June 18, 2026.
• Cidara Therapeutics' 2026 annual meeting of stockholders, which is an alternative vesting trigger for the options.

Key Dates

Keywords

Cidara Therapeutics, CDTX, RA Capital Management, Stock Option, Form 4, SEC Filing, Director Compensation, Equity Grant, Beneficial Ownership, Biotechnology, Pharmaceuticals